Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vacc...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Clinical Immunology Communications |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S277261342300001X |
| _version_ | 1797796340894269440 |
|---|---|
| author | Virginia Meca-Lallana Laura Esparcia-Pinedo Clara Aguirre Carolina Díaz-Pérez Ainhoa Gutierrez-Cobos Mónica Sobrado Estefanía Carabajal Beatriz del Río Noelia Ropero Ramón Villagrasa José Vivancos Francisco Sanchez-Madrid Arantzazu Alfranca |
| author_facet | Virginia Meca-Lallana Laura Esparcia-Pinedo Clara Aguirre Carolina Díaz-Pérez Ainhoa Gutierrez-Cobos Mónica Sobrado Estefanía Carabajal Beatriz del Río Noelia Ropero Ramón Villagrasa José Vivancos Francisco Sanchez-Madrid Arantzazu Alfranca |
| author_sort | Virginia Meca-Lallana |
| collection | DOAJ |
| description | We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2. |
| first_indexed | 2024-03-13T03:31:36Z |
| format | Article |
| id | doaj.art-a3a5627a595c47c39adcb26af5fd23be |
| institution | Directory Open Access Journal |
| issn | 2772-6134 |
| language | English |
| last_indexed | 2024-03-13T03:31:36Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Immunology Communications |
| spelling | doaj.art-a3a5627a595c47c39adcb26af5fd23be2023-06-24T05:20:02ZengElsevierClinical Immunology Communications2772-61342023-12-013613Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugsVirginia Meca-Lallana0Laura Esparcia-Pinedo1Clara Aguirre2Carolina Díaz-Pérez3Ainhoa Gutierrez-Cobos4Mónica Sobrado5Estefanía Carabajal6Beatriz del Río7Noelia Ropero8Ramón Villagrasa9José Vivancos10Francisco Sanchez-Madrid11Arantzazu Alfranca12Demyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainImmunology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, Spain; Corresponding author.Demyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainDemyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainMicrobiology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainDemyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainDemyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainDemyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainImmunology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainPreventive Medicine Unit. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainDemyelinating Diseases Unit, Neurology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainImmunology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainImmunology Department. Hospital Universitario de la Princesa, Calle de Diego de León 62, 28006 Madrid, SpainWe analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.http://www.sciencedirect.com/science/article/pii/S277261342300001X |
| spellingShingle | Virginia Meca-Lallana Laura Esparcia-Pinedo Clara Aguirre Carolina Díaz-Pérez Ainhoa Gutierrez-Cobos Mónica Sobrado Estefanía Carabajal Beatriz del Río Noelia Ropero Ramón Villagrasa José Vivancos Francisco Sanchez-Madrid Arantzazu Alfranca Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs Clinical Immunology Communications |
| title | Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs |
| title_full | Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs |
| title_fullStr | Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs |
| title_full_unstemmed | Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs |
| title_short | Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs |
| title_sort | analysis of humoral and cellular immunity after sars cov 2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs |
| url | http://www.sciencedirect.com/science/article/pii/S277261342300001X |
| work_keys_str_mv | AT virginiamecalallana analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT lauraesparciapinedo analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT claraaguirre analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT carolinadiazperez analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT ainhoagutierrezcobos analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT monicasobrado analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT estefaniacarabajal analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT beatrizdelrio analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT noeliaropero analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT ramonvillagrasa analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT josevivancos analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT franciscosanchezmadrid analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs AT arantzazualfranca analysisofhumoralandcellularimmunityaftersarscov2vaccinationinpatientswithmultiplesclerosistreatedwithimmunomodulatorydrugs |